Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405218 | 0.85 | LAP3 (0.44) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL14064086 | 0.81 | TSHR (0.46) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL3175484 | 0.81 | TSHR (0.46) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL18946366 | 0.81 | TSHR (0.46) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL492011 | 0.79 | LAP3 (0.48) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL9157801 | 0.77 | LAP3 (0.42) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL10911354 | 0.77 | TSHR (0.53) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL4402436 | 0.75 | TSHR (0.40) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL28659627 | 0.75 | TSHR (0.40) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL10201143 | 0.74 | TSHR (0.50) | TSHRTP53TDP1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828393-B2 | Silylalkyloxyaryl compounds and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-11-28 | — | — | US | claimed |
| US-20160159832-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2016-06-09 | — | — | US | claimed |
| WO-2015013322-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-01-29 | — | — | WO | claimed |
| WO-2025024714-A2 | BONE-TARGETED CANONICAL NOTCH INHIBITOR | BIOVENTURES, LLC (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20230330116-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-10-19 | — | — | US | disclosed |
| US-11672811-B2 | Materials and methods for suppressing and/or treating bone related diseases and symptoms | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| US-11497813-B2 | Bortezomib conjugates and methods using same | BIOVINC, LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-11497813-B2 | Bortezomib conjugates and methods using same | BIOVINC, LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20200368259-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-11-26 | — | — | US | disclosed |
| WO-2020220023-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-0546548-B1 | Guanidinyl alkyl-1,1-bis phosphonic acid derivatives, process for their preparation and their use | HOECHST AG (DE) | 1997-05-02 | — | — | EP | disclosed |
| EP-0531253-B1 | N-substituted aminomethanediphosphonic acids | CIBA GEIGY AG (CH) | 1997-01-08 | — | — | EP | disclosed |
| US-5457094-A | Bone disorder | CIBA-GEIGY CORPORATION (US) | 1995-10-10 | — | — | US | disclosed |
| US-5413994-A | Some of the amidines as new compounds; use as calcium metabolism regulators | CIBA-GEIGY CORPORATION (US) | 1995-05-09 | — | — | US | disclosed |
| US-5294608-A | Compounds for treatment of osteoporosis and bone disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-15 | — | — | US | disclosed |
| US-5281748-A | N-substituted aminomethanediphosphonic acids | CIBA-GEIGY CORP. (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0555845-A2 | Steroid derivatives | MITSUBISHI KASEI CORPORATION (JP) | 1993-08-18 | — | — | EP | disclosed |
| EP-0546548-A1 | Guanidinyl alkyl-1,1-bis phosphonic acid derivatives, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-06-16 | — | — | EP | disclosed |
| EP-0531253-A1 | N-substituted aminomethanediphosphonic acids | CIBA-GEIGY AG (CH) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368259-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS | SOST, TSG101, BST2 | TSHR 4492/4885TP53 430/4885TDP1 3096/4885 |
| US-11672811-B2 | Materials and methods for suppressing and/or treating bone related diseases and symptoms | SOST, TSG101, BST2 | TSHR 4492/4885TP53 430/4885TDP1 3096/4885 |
| US-20160159832-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | BCL3, MYLK2, BCL2L13 | TSHR 4239/4885TP53 122/4885TDP1 4243/4885 |
| US-11497813-B2 | Bortezomib conjugates and methods using same | BCR, PSMA6, PSMA5 | TSHR 4516/4885TP53 505/4885TDP1 4145/4885 |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | KLK3, FOLH1, PSMA1 | TSHR 2054/4885TP53 473/4885TDP1 3910/4885 |
| US-20230330116-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS | SOST, TSG101, ACP3 | TSHR 4485/4885TP53 388/4885TDP1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.